Monday , September 25 2017
Home / Multiple Sclerosis

Multiple Sclerosis

Unique Gene Therapy Prevents, Reverses Multiple Sclerosis in Animal Model

Multiple sclerosis can be inhibited or reversed using a novel gene therapy technique that stops the disease’s immune response in mouse models, University of Florida Health researchers have found. By combining a brain-protein gene and an existing medication, the researchers were able to prevent the mouse version of multiple sclerosis. …

Read More »

New Imaging Technique Able to Watch Molecular Dynamics of Neurodegenerative Diseases

WASHINGTON — Researchers have developed a fast and practical molecular-scale imaging technique that could let scientists view never-before-seen dynamics of biological processes involved in neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis. The new technique reveals a sample’s chemical makeup as well as the orientation of molecules making up …

Read More »

FDA Expands Approval of Ipsen’s Dysport for the Treatment of Lower Limb Spasticity in Adults

BASKING RIDGE, N.J.–(BUSINESS WIRE)–Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of Dysport®(abobotulinumtoxinA) for injection for the treatment of spasticity in adults, based on its supplemental Biologics License Application (sBLA) …

Read More »

Celgene Ozanimod Demonstrates Positive Results in Second Late-Stage Trial in Relapsing Multiple Sclerosis

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced that its phase III RADIANCE trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly …

Read More »

Teva and Active Biotech’s Laquinimod Fails to Meet Primary Endpoint in Phase 3 Multiple Sclerosis Trial

JERUSALEM & LUND, Sweden–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS). The primary endpoint in CONCERTO — the evaluation of laquinimod (0.6 mg/daily capsules) versus placebo to evaluate …

Read More »

New Data from Genzyme’s Phase 3 Study Suggest Positive Effects of Aubagio on Cortical Gray Matter Atrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data evaluating the effect of Aubagio® (teriflunomide) on cortical gray matter atrophy in patients with a first clinical episode suggestive of MS will be presented at the 69th American Academy of Neurology (AAN) …

Read More »

Research Moves Closer to Unraveling Mystery Cause of Multiple Sclerosis

A new study has made a major new discovery towards finding the cause of multiple sclerosis (MS), potentially paving the way for research to investigate new treatments. Ahead of MS Awareness Week, which starts today (Monday April 24), an international team involving the University of Exeter Medical School and the …

Read More »

Tecfidera and Tysabri Data Demonstrate Improved Outcomes with Early MS Treatment

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) announced new real-world data that show treatment with its leading multiple sclerosis (MS) therapies, TECFIDERA® (dimethyl fumarate) and TYSABRI® (natalizumab), early in the course of the disease may improve outcomes for people living with relapsing MS. These data were presented at the 69th annual meeting …

Read More »

FDA Approves Genentech’s Ocrevus for Relapsing and Primary Progressive Forms of Multiple Sclerosis

South San Francisco, CA — March 28, 2017 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The …

Read More »

Apitope’s Multiple Sclerosis Drug Demonstrates Positive Results in its Phase IIa Study

Hasselt, Belgium and Chepstow, UK: 21 February 2017 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase …

Read More »